Hypothyroidism causes a tendency for cardiovascular diseases. It was recently shown that thrombin-activatable fibrinolysis inhibitor (TAFI) attenuates fibrinolysis and also fibrin-plasminogen interaction by the removal of lysine and arginine residues from fibrin monomers. The aim of this study was to determine the effects of overt hypothyroidism on the levels of TAFI antigen (TAFI Ag) and TAFI activity (TAFIa). Thirty-one overt primary hypothyroid patients and age-and gender-matched 25 healthy controls were enrolled in the study. Patients were treated with L-thyroxine after the collection of blood samples. Thyroid functions were reevaluated following the achievement of euthyroid status. Thrombin-activatable fibrinolysis inhibitor Ag, tissue plasminogen activator (t-PA), and plasminogen activator inhibitor 1 (PAI-1) levels were measured with the enzyme-linked immunosorbent assay (ELISA). Thrombin-activatable fibrinolysis inhibitor activity was assessed with the chromogenic assay. Thrombin-activatable fibrinolysis inhibitor Ag (1.63% + 0.42% vs 1.32% + 0.36%, P < .01) and TAFIa (14.2 + 4.12 vs 11.6 + 3.49 mg/mL, P < .05) levels were elevated in hypothyroid patient compared to controls. Plasminogen activator inhibitor 1 and t-PA levels were not significantly different between both groups. In hypothyroid patients, TAFI Ag levels were correlated with free T 4 (r ¼ À.373, P < .05) and thyroid-stimulating hormone (TSH) levels (r ¼ .748, P < .001). Regression analysis showed that TSH levels were predictors of TAFI Ag levels (P < .001, b ¼ .671, 95% confidence interval [CI]: 0.008-0.017). Following L-thyroxine treatment, TAFI Ag (1.63% + 0.42%, 1.34% + 0.33%, P < .05) and TAFIa (14.2 + 4.12 mg/mL, 12.0 + 2.77 mg/mL, P < .05) levels were significantly decreased, but t-PA and PAI-1 levels remained unchanged. This results point out that the fibrinolytic activity was decreased in hypothyroid patients, and therefore the achievement of euthyroid status is important in ameliorating the increased risk of cardiovascular disease.
Introduction
Hypothyroidism is an important endocrine disease that is frequently seen among general population and causes a tendency to cardiovascular diseases. 1, 2 Although it is well known that there is a strong relationship between low thyroid hormone levels and the progression of atherosclerosis, some studies have demonstrated a decrease in the fibrinolytic activity in mild hypothyroidism in contrast to the increase in severe hypothyroidism and a bleeding tendency in hypothyroid patients. 3, 4 Published data about the alteration of fibrinolytic activity in hypothyroidism still remain controversial.
The fibrinolytic system is a part of homeostatic mechanism, which plays an important role in the fibrin degradation and angiogenesis. Fibrinolysis is regulated by specific molecular interactions. Plasminogen, synthesized by hepatocytes, is transformed to plasmin by plasminogen activators (tissue plasminogen activator [t-PA], urinary plasminogen activator [u-PA]).
The production of plasmin is also regulated by plasminogen activator inhibitors (plasminogen activator inhibitor [PAI-1, PAI-2, PAI-3], protease nexin). Plasmin induces the hydrolysis of factor V (FV), factor VIII (FVIII), von Willebrand factor (vWF), factor XIII (FXIII), and extracellular matrix protein as well as fibrin. 5 It has been demonstrated that thrombinactivatable fibrinolysis inhibitor (TAFI), which can be isolated from human plasma, plays an important role in hemostatic mechanisms. Thrombin-activatable fibrinolysis inhibitor attenuates the fibrinolytic system by inhibiting the binding of plasminogen to fibrin and causes a tendency to thrombosis. 6, 7 The aim of the current study was to investigate the plasma levels of TAFI antigen (TAFI Ag), TAFI activity (TAFIa), PAI-1, and t-PA in overt primary hypothyroid patients. Additionally, we evaluated the effects of L-thyroxine treatment on fibrinolytic system.
Materials and Method Patients and Controls
Thirty-one overt primary hypothyroid patients were recruited in the study. Primary hypothyroidism was defined on the basis of decreased free T4 concentrations (fT 4 : 0.8-1.9 ng/dL) in association with increased thyroid-stimulating hormone (TSH) concentrations above the normal (TSH: 0.4-4.0 mIU/mL) and low or normal free T 3 concentrations below the normal levels (fT 3 : 1.8-5.0 pg/mL). Among hypothyroid patients, 24 (77.4%) had Hashimoto thyroiditis, 4 (12.9%) had hypothyroidism secondary to treatment of radioactive iodine, and 3 (9.7%) had hypothyroidism secondary to thyroid surgery. Ageand sex-matched control group consisted of the 25 healthy participants with normal TSH and free thyroid hormone levels.
Age, height, weight, systolic, and diastolic blood pressure values of all cases were recorded. Body mass index (BMI) was calculated as body weight divided by square of height. Exclusion criteria included diabetes mellitus, current smoking, alcohol intake, history of cardiovascular and cerebrovascular disease, systemic inflammatory disorders or malignancy, renal and hepatic disorders, coagulation disorders, and the use of drugs that may affect hemostatic parameters (aspirin, oral contraceptives, nonsteroidal anti-inflammatory drugs, lipidlowering drugs, corticosteroids, and anticoagulant drugs . . . ). The study was approved by the local Ethics Committee, and all patients gave their informed consent according to Helsinki declaration for participating into the study.
Blood Sampling and Assay Methods
Blood samples of participants were obtained from antecubital vein without using tourniquet between 08:00 and 09:00 AM after overnight fast. After the disposal of the first 2 mL of the obtained blood, venous blood samples were collected into tubes containing 3.8% sodium citrate in 9:1 volume ratio. Plateletpoor plasma was gained by centrifugation at 2000g for 15 minutes at 4 C. Aliquots of plasma were kept in eppendorfs at À80 C until assay.
Fasting blood glucose (FBG), triglyceride (TG), total cholesterol, and high-density lipoprotein cholesterol (HDL-C) were measured by automated routine procedures (Beckman Coulter LX20, USA). Low-density lipoprotein cholesterol (LDL-C) level was calculated according to Friedewald formula. Thyroid-stimulating hormone, fT4, and fT3 levels were measured by immunometric assay method, chemiluminescent immunoassay method, and competitive immunoassay method, respectively (Immulite 2000; DPC, Los Angeles, California). Thyroid autoantibodies (antithyroglobulin, antithyroid peroxidase antibody) levels were measured by chemiluminescent immunometric assay (Immulite 2000; DPC).
Plasma PAI-1 (Asserachrom; Diagnostica Stago, France) and t-PA (Imubind; American Diagnostica) levels were measured by enzyme-linked immunosorbent assay (ELISA). Thrombin-activatable fibrinolysis inhibitor Ag levels were measured by ELISA (Imuclone; American Diagnostica, USA). The activity of TAFI was determined using a chromogenic method (ACTICHROME; American Diagnostica, USA). All intraassay coefficients of variability were less than 10%. The TAFI Ag, TAFIa, t-PA, and PAI-1 levels were measured at baseline and at the end of study.
L-thyroxine 25 mg/d was started in the hypothyroid patients with the increment of dose to 100 mg/d. Thyroid function tests were reassessed at the end of 8 weeks. Blood samples of euthyroid participants were obtained and stored.
Statistical Analysis
All statistical analyses were performed using SPSS 15.0 software for Windows. Data were expressed as mean + SD. The normality of the distribution of all variables was assessed by the Kolmogorov-Smirnov test. Student t test and Mann-Whitney U test were used for normally distributed and nonparametric variables between the hypothyroid patients and the controls. Pearson correlation analyses and Spearman rank correlation test were used. Thyroid-stimulating hormone levels of hypothyroid patients were divided into 3 subgroups to analyze the relationship between TAFI, TAFIa, and TSH by frequencies of descriptive statistics. The data of TSH groups were compared with 1-way analysis of variance (ANOVA) test and Kruskal-Wallis test. The variables of before and after treatment were assessed with Wilcoxon-signed ranks tests. Correlation coefficients and stepwise linear regression were calculated for thyroid hormones and fibrinolytic parameters in relation to the other continuous clinical and laboratory parameters.
Results
The demographic, clinical, and laboratory data of hypothyroid and control participants are shown in Table 1 . The groups were well matched with regard to gender, age, BMI, and blood pressure. At baseline, the means of total cholesterol, HDL-C, and LDL-C levels were higher in hypothyroid patients than the controls (P < .01, P < .05, and P < .01, respectively). The free thyroid hormone levels in hypothyroid patients were at the lower limit of the normal ranges, and TSH levels were above the normal. When compared to the control group, fT3 and fT4 levels of hypothyroids were low, TSH levels were high (P < .001, P < .001, P < .001, respectively).
Plasma levels of TAFI Ag and TAFIa in hypothyroid group were significantly higher when compared with the control group (P < .01, P < .05), whereas no significant differences were detected in plasma t-PA and PAI-1 levels among groups ( Table 1 ).
In the correlation analysis of the data of the hypothyroid group, TAFI Ag level was found to be negatively associated with fT4 (P < .05, r ¼ À.373) and to be positively associated with TSH levels (P < .001, r ¼ .748). There was no association between plasma TAFIa, t-PA, and PAI-1 levels, and other clinical and laboratory parameters of hypothyroid group. Logistic regression analysis showed that the TSH levels associated with the TAFI Ag levels independent of the other risk factors such as age, BMI, hyperlipidemia (P < .001, b ¼ 0.671, 95% confidence interval [CI]: 0.008-0.017).
The hypothyroid patients were further subdivided into 3 subgroups according to their TSH levels. (group 1: n ¼ 8, TSH 37 mIU/mL; group 2: n ¼ 8, TSH 37.1-54.6 mIU/mL; group 3: n ¼ 15, TSH 56.7-75 mIU/mL). We found no difference in plasma TAFI Ag levels groups 1 and 2 (P > .05). However, TAFI Ag levels were significantly higher in the group 3 than the groups 1 and 2 (P < .01, P < .05, respectively). Plasma TAFIa, t-PA, and PAI-1 levels of all 3 groups did not show any significant difference (Table 2) .
While the mean TSH levels (2.34 + 1.05 mIU/mL), which were measured after L-thyroxine treatment of hypothyroid group (P < .001), showed a significant decrease in comparison to the levels before the treatment, an increase was remarked in fT3 and fT4 levels (3.09 + 0.72 pg/mL, 1.43 + 0.27 ng/dL, respectively). In euthyroid state, the TG levels (137.9 + 75.8 mg/dL) did not show any difference compared to that before the treatment (P > .05); but remarkably, lower levels of total cholesterol (191.6 + 42.1 mg/dL), LDL-C (123.5 + 43.4 mg/dL), and HDL-C (48.0 + 8.9 mg/dL) levels were measured (P < .01, P < .01, P < .05, respectively).
In addition, we found that the plasma TAFI Ag (1.34% + 0.33%) and TAFIa levels (12.0 + 2.77 mg/mL) were significantly lower after L-thyroxine treatment of hypothyroid group than before the treatment (P < .05, P < .05, respectively). However, the mean of plasma t-PA (8.73 + 6.97 ng/mL) and PAI-1 (1.59 + 0.32 ng/mL) levels did not significantly differ after the treatment (P > .05, P > .05, respectively; Figure 1 ).
Discussion
In the current study, the plasma concentrations of TAFI Ag and TAFIa were significantly increased in patients with overt hypothyroidism as compared to healthy participants. We found that the fibrinolytic activity substantially decreases when the hypothyroidism gets more severe. In addition, L-thyroxine treatment caused a decrease in plasma TAFI Ag and TAFIa concentrations. These results suggest that hypothyroidism plays a role in the development of tendency to procoagulant state, and the achievement of euthyroidism is an important goal for the prevention of cardiovascular events in patients with hypothyroidism.
The association between the overt hypothyroidism and atherosclerosis is well known for many years. 8 In a study, enrolled patients, who underwent coronary angiography, it was shown that the replacement of L-thyroxine prevented the progress of the atherosclerotic cardiac disease in overt hypothyroid patients. 9 Changes in coagulation system play an important role in the development and progress of the atherosclerosis. 10 Although the coagulation system is sufficiently investigated in overt and subclinical hypothyroidism for many years, the results of these studies are controversial. A bleeding tendency has been described in some studies, 11 whereas others have suggested a hypercoagulable state in overt hypothyroidism. 4, 12, 13 Erem et al 4 showed that hypothyroidism was a risk factor for Figure 1 . Thrombin-activatable fibrinolysis inhibitor (TAFI) Ag, TAFIa, tissue plasminogen activator (t-PA), and plasminogen activator inhibitor (PAI)-1 levels in hypothyroid group before and after l-thyroxine replacement therapy. developing thrombosis and coronary heart disease because of the high PAI-1 levels. In contrary, Chadarevian et al 3 proposed that mild hypothyroidism (TSH 10-50 mU/mL) attenuated the fibrinolytic activity by increasing the t-PA and PAI-1 levels, while the severe hypothyroidism (TSH >50 mU/mL) enhanced the fibrinolytic activity and rendered a predisposition to hemorrhage via increased t-PA and PA1-1 levels. In another study, same investigators showed that the fibrinolytic activity transiently decreased after the treatment of severe hypothyroid patients. 14 In the current study, we found that the plasma t-PA and PAI-1 levels in hypothyroid patients did not differ from those in healthy participants. Moreover, no correlation was found between the TSH levels and these 2 parameters. No important change in t-PA and PAI-1 levels was determined after the replacement of L-thyroxine. These observations suggest that it is not clear whether t-PA and PAI-I levels are responsible for homeostatic changes in hypothyroid patients. Thrombin-activatable fibrinolysis inhibitor is a key modulator of fibrinolysis, which is synthesized in the liver and adipocyte tissue. Thrombin-activatable fibrinolysis inhibitor Ag circulates as an inactive proenzyme in the blood stream. The active form, TAFIa, plays a role in the regulation of coagulation, fibrinolysis, and inflammation. 15, 16 It was reported that the elevation of the TAFI Ag is a cause of hypofibrinolysis in several endocrinologic disorders such as obesity 17 and diabetes mellitus. 18 In the published literature, there were several studies investigating plasma TAFI Ag or TAFIa levels in overt hypothyroidism. In a study, increased levels of TAFI Ag have been reported in patients with hypothyroidism. 19 However, the authors found no significant correlation between plasma TAFI Ag and thyroid hormones. Akinci et al 20 reported higher plasma TAFI Ag levels that were correlated with degree of thyroid levels in hypothyroid patients. They also found that L-thyroxine replacement treatment was effective in lowering TAFI Ag. In a recent study, Cetinkalp et al 21 observed that TAFIa level was increased in hypothyroid patients and did not change in response to L-thyroxine treatment. In our study, we assessed that the TAFI Ag and TAFIa levels in hypothyroid patients were higher than the controls. Based on our findings, thyroid failure appeared to influence the circulating levels of TAFI Ag. After separating the subgroups according to TSH levels, it was remarked that TAFI Ag level was high in severe hypothyroid patients. However, no significant correlation was found between TAFIa, thyroid hormones, and other homeostatic markers. The reason that can explain this lack of correlation is not known. We did not also find any significant association between the levels of TAFI Ag and the TAFIa. We speculated that this finding is probably related to the consumption and the shorter half-life of TAFIa than TAFI Ag. Another important result of this study was that both TAFI Ag and TAFIa were decreased after achieving euthyroid state with L-thyroxine treatment. Decreased clearance and/or increased production by liver and adipose tissue might cause increased TAFI Ag and TAFIa levels in hypothyroidism. Thus, we supposed that TAFI Ag and TAFIa might play a role in the disturbance in fibrinolytic system in hypothyroid patients.
Lipid abnormalities are reported to be more common in patients with overt hypothyroidism and are thought to cause predisposition to cardiovascular disease. 22 Hypothyroidism causes an accumulation of LDL-C due to a reduction in the activity and in the number of cell surface receptors for LDL. 23 Accordingly, in the current study, total cholesterol and LDL-C levels in hypothyroid patients were higher than the controls. Several studies reported that dyslipidemia contributed to endothelial dysfunction that was the main mechanism of decreased fibrinolysis and enhanced thrombin generation. Aso et al 24 reported that plasma TAFI Ag positively and independently correlated with LDL-C levels in diabetes mellitus. However, Guven at al 25 showed that plasma TAFI Ag levels significantly decreased after statin treatment, although there was no correlation between TAFI Ag levels and baseline lipid parameters in patients with hypercholesterolemia. Our results also showed no association among TAFI Ag, TAFIa, and lipid parameters in hypothyroidism.
The result of current study showed that the increase of TAFI Ag and TAFIa, which were correlated with severity of the hypothyroidism, contributed to the reduced fibrinolysis and the predisposition to cardiovascular diseases. Because there was no significant change in t-PA and PAI-1 levels, we suggested that the TAFI Ag was more effective marker for the inhibition of the fibrinolysis in hypothyroidism. In addition, the significant decrease in TAFI Ag and TAFIa levels achieved after euthyroidism supported the importance of L-thyroxine treatment in lowering the risk in cardiovascular diseases. In conclusion, we were of the opinion that the early onset of the treatment was important in abolishing the unfavorable effects on the fibrinolytic system and in reducing the predisposition to cardiovascular diseases. Longitudinal prospective studies, which should include large number of patients, are required to understand the causal relationship between TAFI and hypothyroidism.
